PYRROLO[3,2-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES

• US 20160168150A1
• Filed: 06/26/2014
• Published: 06/16/2016
• Est. Priority Date: 06/27/2013
• Status: Active Grant

• Current Assignee: Janssen Sciences Ireland Unlimited Company (Johnson & Johnson)
• Original Assignee: Janssen Sciences Ireland UC (Johnson & Johnson)
• Inventors: PIETERS, Serge Maria Aloysius, EMBRECHTS, Werner, MC GOWAN, David Craig, LAST, Stefaan Julien, JONCKERS, Tim Hugo Maria, RABOISSON, Pierre Jean-Marie Bernard
• Granted Patent: US 10,385,054 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 487/04 Ortho-condensed systems

Abstract

This invention concerns pyrrolo[3,2-d]pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treatment and/or therapy of diseases.

Claims

1. A compound of formula (I)

2. A compound as claimed in claim 1, wherein R₃ is a CH₂-aryl group.

3. A compound as claimed in claim 1, wherein R₃ and R₄ are both CH₂-aryl groups, wherein R₃ is optionally substituted by one or more substituents independently selected from the group consisting of halogen, aryloxy, aryl, alkylamino, dialkylamino, C_1-6 alkyl, —

CO₂H, —

CO₂C_1-6 alkyl, —

CO₂NH₂, —

SO₂NH₂, —

CN and C_1-6 alkoxy, and wherein R₄ is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, C_1-6 alkyl, C_3-7 cycloalkyl, C_2-6 alkenyl and aryl, wherein said aryl is optionally further substituted by C_1-6 alkyl, and said C_3-7 cycloalkyl is optionally further substituted by C_1-6 alkyl.

4. A compound according to claim 1 wherein R₁ is fluorine and R₂ is hydrogen.

5. A compound according to claim 1 having the following chemical structure:

6. A pharmaceutical composition comprising a compound according to claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

8. A method of modulating TLR 7 to treat a viral infection comprising administering a therapeutically effective amount of at least one compound as claimed in claim 1.

9. A compound as claimed in claim 1, wherein R₂ and R₁ are H.

10. A compound as claimed in claim 9, wherein R₃ is selected from the group consisting of

11. A compound as claimed in claim 1, wherein R₄ is alkylaryl.

12. A compound as claimed in claim 10, wherein R₄ is alkylaryl.

13. A compound as claimed in claim 10 wherein R₄ is selected from the group consisting of

14. A compound as claimed in claim 1, wherein R₄ is C_1-6 alkyl.

15. A compound as claimed in claim 10, wherein R₄ is C_1-6 alkyl.

16. A compound as claimed in claim 1, wherein

R₂ and R₁ are H,

17. A compound as claimed in claim 1 wherein

R₂ and R₁ are H,

18. A compound as claimed in claim 1, wherein

R₂ and R₁ are H,

20. A pharmaceutical composition comprising a compound as claimed in claim 5 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

7. (canceled)

19. A compound selected from the group consisting of